Prospective evaluation of vitamin E for hot flashes in breast cancer survivors
Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR, et al.
Published in J Clin Oncol, Vol. 16 (2), pp. 495-500
Methodology
Placebo-controlled, randomised, double-blind crossover trial in breast cancer survivors with hot flashes: after a baseline week, 4 weeks of vitamin E 800 IU daily and 4 weeks of identical placebo, in random order, with daily hot flash diaries.
Key Findings
In the 105 women who finished the first period, hot flash frequency fell by 25% with vitamin E and 22% with placebo (P = .90). The crossover analysis found about one fewer hot flash per day with vitamin E than placebo (P <= .05). At the end, 32% preferred vitamin E and 29% placebo; no toxicity was seen in 120 women.
Conclusions
Vitamin E produced a statistically significant but clinically marginal reduction in hot flashes.
Limitations
Short treatment periods (4 weeks each); breast cancer survivors only, so results may differ in other women; large placebo response.
Supplements Studied
the clinical magnitude of this reduction was marginal
Outcomes Measured
the clinical magnitude of this reduction was marginal
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.